GlassScriptPhysician profile
Phuc Tuan Huynh
NPI 1922005602
$18,170.07
in general payments reported to CMS, 2019-2025
45 companies · $2,704 in 2025
The $2,704 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,826 · 2020: $1,194 · 2021: $2,349 · 2022: $2,741 · 2023: $2,968 · 2024: $2,388 · 2025: $2,704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,752 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200 · Gift: $59.40 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,752.42 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200.00 |
| Gift | $59.40 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,002.37 | 2019-2025 | Airsupra, Lokelma, Farxiga |
| Abbott Laboratories | $1,860.68 | 2022-2025 | Freestyle Libre 3 |
| Nestle Healthcare Nutrition INC. | $1,225.10 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,091.07 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $986.12 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $853.73 | 2019-2025 | Ingrezza |
| Mannkind Corporation | $818.72 | 2020-2023 | Afrezza |
| Bayer Healthcare Pharmaceuticals INC. | $672.11 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $568.98 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $562.89 | 2019-2025 | Austedo Xr, Austedo Xr |
| Novo Nordisk INC | $544.09 | 2019-2025 | Wegovy, Ozempic |
| Sunovion Pharmaceuticals INC. | $533.31 | 2019 | |
| Corcept Therapeutics | $529.84 | 2023-2025 | Korlym |
| Pfizer INC. | $520.95 | 2019-2025 | |
| Amgen INC. | $386.38 | 2024-2025 | Krystexxa, Repatha |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phuc Huynh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.